Volume 9, Issue 4, October 2026

Review Articles

Sandra Kleinau
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 495–507, https://doi.org/10.1093/abt/tbag032
Qianhui Jiang and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 508–520, https://doi.org/10.1093/abt/tbag039

Statement of Significance This review summarizes how AI is moving antibody developability assessment beyond affinity-first screening toward multi-objective design. We highlight data resources, property predictors, and optimization strategies that help prioritize balanced candidates while accounting for assay context, uncertainty, and antibody format.

Mini Review

Haosheng Feng and Bin Liu
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 566–575, https://doi.org/10.1093/abt/tbag042

Statement of Significance This mini-review highlights emerging antibody conjugates with ultrahigh DARs, focusing on polymer- and nanoparticle-based platforms. By expanding payload capacity, these strategies enable alternative, more selective, and less toxic drugs and provide key design principles for overcoming DAR limitations in next-generation antibody therapeutics.

Research Articles

Zahra Esmaeili and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 471–479, https://doi.org/10.1093/abt/tbag025
Kasandra Bélanger and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 480–494, https://doi.org/10.1093/abt/tbag033

Statement of Significance This work demonstrates the feasibility of an mRNA-LNP immunization and cell-based panning strategy for the rapid discovery of camelid nanobodies (VHHs) recognizing conformational epitopes on native membrane proteins. The approach yielded high-affinity VHHs capable of blocking spike-angiotensin-converting enzyme 2 interactions in a surrogate cell-based assay, demonstrating its utility for generating binders with functional potential against complex viral antigens.

Deyong Song and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 521–534, https://doi.org/10.1093/abt/tbag040

Statement of Significance These findings demonstrate that hinge-region cysteine engineering can enable homogeneous DAR6 ADCs and highlight O-glycosylation as an associated molecular feature of this strategy that appears functionally tolerated in ADC-relevant assays.

Marlena Surowka and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 535–549, https://doi.org/10.1093/abt/tbag038

Statement of Significance This research introduces a novel approach to T cell redirection to tumors using hapten-based adaptors and antibody-based T cell engagers, with fM affinity between the components. This addresses current limitations in cancer immunotherapy, including tumor heterogeneity, limited stability of the adaptor-engager complexes, or complexity in computational design of tumor ligands.

Zhizhong Wei and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 550–565, https://doi.org/10.1093/abt/tbag041

Statement of Significance We obtained a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody, P23, binding adjacent to the FP in the S2 subunit. We engineered an IgG-like bispecific protein, Bs-ACE2-P23, combining P23 with the viral receptor ACE2, and demonstrated its broad and potent neutralization against SARS-CoV-2 variants, offering a promising strategy for broad-spectrum antiviral therapeutics.

Koji Hashimoto and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 576–594, https://doi.org/10.1093/abt/tbag043

This study integrates whole-cell phage display selection with CRISPR-Cas9-based target deconvolution to identify AML-selective antibodies and their cognate antigens. The resulting antibody–antigen pairs, including candidates evaluated in CAR-T cell formats, provide a framework for accelerating immunotherapy target discovery.

Gangling Xu and others
Antibody Therapeutics, Volume 9, Issue 4, October 2026, Pages 595–605, https://doi.org/10.1093/abt/tbag048

Statement of Significance This large-scale analysis of 51 commercial antibodies defines the real-world profile of sequence variants. The findings guide manufacturing control and support rational regulatory decision-making for antibody therapeutics.